Research And Development Expense of ProQR Therapeutics N.V. from 31 Dec 2015 to 30 Sep 2024

Taxonomy & unit
ifrs-full: EUR
Summary
ProQR Therapeutics N.V. quarterly and annual Research And Development Expense in EUR history and change rate from 31 Dec 2015 to 30 Sep 2024.
  • ProQR Therapeutics N.V. Research And Development Expense for the quarter ending 30 Sep 2024 was €9,414,000, a 73% increase year-over-year.
  • ProQR Therapeutics N.V. Research And Development Expense for the twelve months ending 30 Sep 2024 was €33,478,000, a 19% increase year-over-year.
  • ProQR Therapeutics N.V. annual Research And Development Expense for 2023 was €25,148,000, a 51% decline from 2022.
  • ProQR Therapeutics N.V. annual Research And Development Expense for 2022 was €50,867,000, a 20% increase from 2021.
  • ProQR Therapeutics N.V. annual Research And Development Expense for 2021 was €42,220,000, a 11% increase from 2020.
Source SEC data
View on sec.gov
Research And Development Expense, Trailing 12 Months (EUR)
Research And Development Expense, Quarterly (EUR)
Research And Development Expense, YoY Quarterly Change (%)
Research And Development Expense, Annual (EUR)
Research And Development Expense, YoY Annual Change (%)

ProQR Therapeutics N.V. Quarterly Research And Development Expense (EUR)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 €33,478,000 €9,414,000 +€3,968,000 +73% 01 Jul 2024 30 Sep 2024 6-K 07 Nov 2024 2024 Q3
Q2 2024 €29,510,000 €7,048,000 +€1,139,000 +19% 01 Apr 2024 30 Jun 2024 6-K 08 Aug 2024 2024 Q2
Q1 2024 €28,371,000 €9,283,000 +€3,223,000 +53% 01 Jan 2024 31 Mar 2024 6-K 09 May 2024 2024 Q1
Q4 2023 €25,148,000 €7,733,000 -€2,966,000 -28% 01 Oct 2023 31 Dec 2023 20-F 13 Mar 2024 2023 FY
Q3 2023 €28,114,000 €5,446,000 -€9,906,000 -65% 01 Jul 2023 30 Sep 2023 6-K 07 Nov 2024 2024 Q3
Q2 2023 €38,020,000 €5,909,000 -€5,540,000 -48% 01 Apr 2023 30 Jun 2023 6-K 08 Aug 2024 2024 Q2
Q1 2023 €43,560,000 €6,060,000 -€7,307,000 -55% 01 Jan 2023 31 Mar 2023 6-K 09 May 2024 2024 Q1
Q4 2022 €50,867,000 €10,699,000 -€1,757,000 -14% 01 Oct 2022 31 Dec 2022 20-F 13 Mar 2024 2023 FY
Q3 2022 €52,624,000 €15,352,000 +€4,228,000 +38% 01 Jul 2022 30 Sep 2022 6-K 07 Nov 2023 2023 Q3
Q2 2022 €48,396,000 €11,449,000 +€1,714,000 +18% 01 Apr 2022 30 Jun 2022 6-K 03 Aug 2023 2023 Q2
Q1 2022 €46,682,000 €13,367,000 +€4,462,000 +50% 01 Jan 2022 31 Mar 2022 6-K 16 May 2023 2023 Q1
Q4 2021 €42,220,000 €12,456,000 +€4,037,000 +48% 01 Oct 2021 31 Dec 2021 6-K 24 Feb 2022 2021 FY
Q3 2021 €38,183,000 €11,124,000 +€2,820,000 +34% 01 Jul 2021 30 Sep 2021 6-K 09 Nov 2022 2022 Q3
Q2 2021 €35,363,000 €9,735,000 +€1,148,000 +13% 01 Apr 2021 30 Jun 2021 6-K 04 Aug 2022 2022 Q2
Q1 2021 €34,215,000 €8,905,000 -€3,920,000 -31% 01 Jan 2021 31 Mar 2021 6-K 05 May 2022 2022 Q1
Q4 2020 €38,135,000 €8,419,000 -€5,512,000 -40% 01 Oct 2020 31 Dec 2020 6-K 24 Feb 2022 2021 FY
Q3 2020 €43,647,000 €8,304,000 -€2,770,000 -25% 01 Jul 2020 30 Sep 2020 6-K 04 Nov 2021 2021 Q3
Q2 2020 €46,417,000 €8,587,000 -€936,000 -9.8% 01 Apr 2020 30 Jun 2020 6-K 05 Aug 2021 2021 Q2
Q1 2020 €47,353,000 €12,825,000 +€862,000 +7.2% 01 Jan 2020 31 Mar 2020 6-K 07 May 2020 2020 Q1
Q4 2019 €46,491,000 €13,931,000 01 Oct 2019 31 Dec 2019 6-K 25 Feb 2021 2020 FY
Q3 2019 €11,074,000 +€4,777,000 +76% 01 Jul 2019 30 Sep 2019 6-K 16 Nov 2020 2020 Q3
Q2 2019 €9,523,000 +€3,533,000 +59% 01 Apr 2019 30 Jun 2019 6-K 06 Aug 2020 2020 Q2
Q1 2019 €11,963,000 01 Jan 2019 31 Mar 2019 6-K 07 May 2020 2020 Q1
Q3 2018 €6,297,000 01 Jul 2018 30 Sep 2018 6-K 12 Nov 2019 2019 Q3
Q2 2018 €5,990,000 -€1,562,000 -21% 01 Apr 2018 30 Jun 2018 6-K 07 Aug 2019 2019 H1
Q2 2017 €7,552,000 01 Apr 2017 30 Jun 2017 6-K 08 Aug 2018 2018 Q2

ProQR Therapeutics N.V. Annual Research And Development Expense (EUR)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 €25,148,000 -€25,719,000 -51% 01 Jan 2023 31 Dec 2023 20-F 13 Mar 2024 2023 FY
2022 €50,867,000 +€8,647,000 +20% 01 Jan 2022 31 Dec 2022 20-F 13 Mar 2024 2023 FY
2021 €42,220,000 +€4,085,000 +11% 01 Jan 2021 31 Dec 2021 20-F 13 Mar 2024 2023 FY
2020 €38,135,000 -€8,356,000 -18% 01 Jan 2020 31 Dec 2020 20-F 29 Mar 2023 2022 FY
2019 €46,491,000 +€16,977,000 +58% 01 Jan 2019 31 Dec 2019 20-F 29 Apr 2022 2021 FY
2018 €29,514,000 -€1,639,000 -5.3% 01 Jan 2018 31 Dec 2018 20-F 24 Mar 2021 2020 FY
2017 €31,153,000 -€770,000 -2.4% 01 Jan 2017 31 Dec 2017 20-F 31 Mar 2020 2019 FY
2016 €31,923,000 +€8,522,000 +36% 01 Jan 2016 31 Dec 2016 20-F 28 Mar 2019 2018 FY
2015 €23,401,000 01 Jan 2015 31 Dec 2015 20-F 30 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.